Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

Summary

This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.

Timeline

Start

2019-08-01

Primary completion

2021-12-31

Completion

2022-07-31

Drugs

Indications